Brought to you by

Entasis nets $70mm via IPO
31 Mar 2021
Executive Summary
Antibiotics developer Entasis Therapeutics Holdings Inc. netted $69.75mm in its initial public offering of 5mm common shares priced at $15. The company had planned to sell 4.4mm shares between $16 and $18 each.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement